PYRROLO- AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE-7 HIBITORS
DE602015092977T2Active Publication Date: 2026-02-04VALO HEALTH INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602015092977
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-12-30
- Filing Date
- 2015-12-29
- Publication Date
- 2026-02-04
- Estimated Expiration
- 2035-12-29
AI Technical Summary
Technical Problem
Current treatments lack effective and potent small molecule inhibitors for ubiquitin-specific protease 7 (USP7) to address various diseases and disorders associated with its activity, including cancer, neurodegenerative diseases, and viral infections.
Method used
Development of compounds of Formula (I) and their pharmaceutically acceptable salts that inhibit USP7 activity, offering a novel approach to treat diseases by modulating USP7 enzyme function.
Benefits of technology
The compounds provide improved efficacy and safety in treating USP7-related diseases such as cancer, neurodegenerative diseases, and viral infections by effectively inhibiting USP7, providing a novel pharmacological strategy for these conditions.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.